6-Methoxymellein
Based on 1 Customer Validation
6-Methoxymellein, a phytoalexin, is a NF-κB inhibitor. 6-Methoxymellein reduces nuclear localization and DNA binding activity of NF-κB p65 and p50 subunits. 6-Methoxymellein decreases mRNA transcription and secretion of IL-6 and IL-8. 6-Methoxymellein reduces the proportion of CD44+/CD24− breast cancer cells, decreases expression of c-Myc, Sox-2 and Oct4, inhibits proliferation and migration of breast cancer cells, and reduces mammosphere growth. 6-Methoxymellein inhibits fungal growth of Trichophyton rubrum and Botrytis cinerea, and inhibits Trichophyton rubrum biofilm formation via hyphal disintegration. 6-Methoxymellein can be used for the research of breast cancer, tinea corporis, and carrot post-harvest storage rot.
For research use only. We do not sell to patients.
- Purity : 99.01%
- CAS No.: 13410-15-6
- Formula: C11H12O4
- Molecular Weight:208.21
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
NF-κB |
IL-6 |
IL-8 |
In Vitro
6-Methoxymellein (0.5-3 mM; 24 h) suppresses proliferation of MDA-MB-231 and MCF-7 human breast cancer cells in a concentration-dependent manner, with significant inhibition starting at 0.8 mM for MDA-MB-231 cells and 0.5 mM for MCF-7 cells after 24-hour incubation[1].
6-Methoxymellein (0.2-1 mM, 0.5-1 mM; 7-day culture period) inhibits mammosphere formation by MDA-MB-231 and MCF-7 human breast cancer cells, reducing mammosphere size, number, and formation efficiency in a concentration-dependent manner, with maximum inhibition at 1 mM[1].
6-Methoxymellein (1 mM; 24 h) significantly inhibits migration of MDA-MB-231 and MCF-7 human breast cancer cells[1].
6-Methoxymellein (0.5-1 mM; 7-day culture period) inhibits colony formation by MDA-MB-231 and MCF-7 human breast cancer cells in a concentration-dependent manner, with maximum inhibition at 1 mM after 7 days of culture[1].
6-Methoxymellein (1 mM; 24 h) reduces the proportion of CD44+/CD24− breast cancer stem-like cells in MDA-MB-231 cultures from 80.3% to 41.6% after 24-hour incubation[1].
6-Methoxymellein (1 mM; 48 h) reduces protein expression of the stemness markers c-Myc, Sox-2, and Oct4 in MDA-MB-231 human breast cancer cell-derived mammospheres after 2 days of treatment[1].
6-Methoxymellein (1 mM; 48 h) suppresses nuclear localization of NF-κB p65 and p50 in MDA-MB-231 human breast cancer cell-derived mammospheres after 48-hour incubation, without altering total cellular levels of these subunits[1].
6-Methoxymellein (1 mM; 1, 2, 3 days post-treatment) inhibits growth of MDA-MB-231 human breast cancer cell-derived mammosphere cells over a 3-day period[1].
6-Methoxymellein (1 mM) inhibits NF-κB DNA binding activity in nuclear extracts from MDA-MB-231 human breast cancer cell-derived mammospheres[1].
6-Methoxymellein (1 mM; 48 h) significantly reduces secretion of IL-6 and IL-8 by MDA-MB-231 human breast cancer cell-derived mammospheres after 2 days of treatment[1].
6-Methoxymellein (1 mM; 48 h) significantly reduces mRNA transcription of IL-6 and IL-8 in MDA-MB-231 human breast cancer cell-derived mammospheres after 2 days of treatment[1].
6-Methoxymellein (6.25-200 μg/mL) potently inhibits growth of the Trichophyton rubrum T.R.1085 S isolate, with an MIC of 6.25 μg/mL, and produces increasing inhibition zone diameters with increasing concentrations up to 29 mm at 200 μg/mL[2].
6-Methoxymellein (1.5625-200 μg/mL) dose-dependently inhibits biofilm formation by the Trichophyton rubrum T.R.1085 S isolate, reaching a maximum inhibition of 68.38% at 200 μg/mL[2].
6-Methoxymellein (6-MM) (>30 μg/g tissue; 1-2 weeks) accumulated in UV-C treated carrot (Daucus carota L.) slices inhibits growth of Botrytis cinerea and Sclerotinia sclerotiorum at cold storage temperatures (1°C, 4°C), with concentrations above 30 μg/g tissue inhibiting B. cinerea and maximum inhibition at ~60 μg/g, leading to up to 88.5% reduction in fungal growth[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231, MCF-7 human breast cancer cells
-
Concentration:0.5 mM, 0.8 mM, 1 mM, 2 mM, 3 mM
-
Incubation Time:24 h
-
Result:Suppressed cell proliferation in a concentration-dependent manner.
Exhibited significant proliferation inhibition at concentrations ≥0.8 mM for MDA-MB-231 cells, with the strongest inhibition at 3 mM.
Exhibited significant proliferation inhibition at concentrations ≥0.5 mM for MCF-7 cells, with the strongest inhibition at 3 mM.
-
Cell Line:MDA-MB-231, MCF-7 human breast cancer cells
-
Concentration:1 mM
-
Incubation Time:24 h
-
Result:Markedly reduced the number of migrated MDA-MB-231 and MCF-7 cells compared to untreated controls.
-
Cell Line:MDA-MB-231 human breast cancer cell-derived mammospheres
-
Concentration:1 mM
-
Incubation Time:48 h
-
Result:Decreased the protein expression levels of c-Myc, Sox-2, and Oct4 compared to untreated controls.\nDid not affect total cellular levels of NF-κB p65 or p50.
Significantly reduced the nuclear levels of NF-κB p65 and p50 compared to untreated controls, while cytosolic levels remained unchanged.
-
Cell Line:MDA-MB-231 human breast cancer cell-derived mammospheres
-
Concentration:1 mM
-
Incubation Time:48 h
-
Result:Significantly reduced the relative mRNA expression levels of IL-6 and IL-8 compared to untreated controls.
Chemical Information
-
CAS No. 13410-15-6
-
Appearance Solid
-
Molecular Weight 208.21
-
Formula C11H12O4
-
Color Orange to reddish brown
-
SMILES
OC1=C2C(C[C@H](OC2=O)C)=CC(OC)=C1
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (480.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.01 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (12.01 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Protocol for Electrophoretic Mobility Shift Assay (EMSA)
Electrophoretic mobility shift assay detects protein-nucleic acid binding by incubating a labeled DNA or RNA probe with purified protein or cell extract, then separating free probe from slower-migrating protein-probe complexes on a native gel. For cancer cells, primary neurons, mouse tumor samples, intestinal organoids, inflammatory macrophages, or drug-treated samples, EMSA can measure transcription-factor DNA binding or RNA-binding protein activity in extracts, but it does not directly measure transcription, protein expression, or chromatin occupancy in intact cells. Specificity is judged by competition with unlabeled wild-type probe, failure of mutated or unrelated competitors to compete, and antibody supershift or disruption when the binding protein identity must be confirmed.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Fungal Biofilm Culture
Fungal biofilm culture is an in vitro method for growing surface-attached fungal communities, most commonly Candida albicans, on abiotic substrates such as polystyrene wells, silicone elastomer, or polymethylmethacrylate; the assay models adhesion, proliferation, filamentation, extracellular-matrix-associated maturation, and dispersion. Biofilm output can be read by optical density at 600 nm for adherent biomass, XTT reduction for metabolic activity, CFU recovery for viable attached or dispersed cells, and microscopy for architecture.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.8028 mL | 24.0142 mL | 48.0284 mL | 120.0711 mL |
| 5 mM | 0.9606 mL | 4.8028 mL | 9.6057 mL | 24.0142 mL | |
| 10 mM | 0.4803 mL | 2.4014 mL | 4.8028 mL | 12.0071 mL | |
| 15 mM | 0.3202 mL | 1.6009 mL | 3.2019 mL | 8.0047 mL | |
| 20 mM | 0.2401 mL | 1.2007 mL | 2.4014 mL | 6.0036 mL | |
| 25 mM | 0.1921 mL | 0.9606 mL | 1.9211 mL | 4.8028 mL | |
| 30 mM | 0.1601 mL | 0.8005 mL | 1.6009 mL | 4.0024 mL | |
| 40 mM | 0.1201 mL | 0.6004 mL | 1.2007 mL | 3.0018 mL | |
| 50 mM | 0.0961 mL | 0.4803 mL | 0.9606 mL | 2.4014 mL | |
| 60 mM | 0.0800 mL | 0.4002 mL | 0.8005 mL | 2.0012 mL | |
| 80 mM | 0.0600 mL | 0.3002 mL | 0.6004 mL | 1.5009 mL | |
| 100 mM | 0.0480 mL | 0.2401 mL | 0.4803 mL | 1.2007 mL |
6-Methoxymellein Related Classifications
HY-N19791 Related Classifications
Powered by Bioz